Clinical characteristics and survival outcomes of newly diagnosed multiple myeloma patients presenting with extramedullary disease: A retrospective study. (April 2022)
- Record Type:
- Journal Article
- Title:
- Clinical characteristics and survival outcomes of newly diagnosed multiple myeloma patients presenting with extramedullary disease: A retrospective study. (April 2022)
- Main Title:
- Clinical characteristics and survival outcomes of newly diagnosed multiple myeloma patients presenting with extramedullary disease: A retrospective study
- Authors:
- Gao, Shuang
Li, Qihui
Dong, Fei
Yang, Ping
Chen, Yingtong
Wang, Jing
Wang, Yanfang
Jing, Hongmei - Abstract:
- Abstract: The aim of study was to assess the clinical characteristics, survival outcomes of newly diagnosed multiple myeloma (NDMM) patients with extramedullary disease (EMD). We retrospectively reviewed and compared the clinical features and outcomes in 226 MM patients with or without EMD at their diagnosis. EMD patients were subsequently divided into bone-related (EMD-B) and soft-tissue related (EMD-S). EMD group was composed of 29.2% of the patients and the incidence of EMD-B and EMD-S was 19.0% and 10.2% respectively. EMD at diagnosis had greater prevalence of IGH/FGFR3 translocation (7.6% vs 2.5%, p = 0.028) and a worse objective response rate (75% vs 88.9%, p = 0.015). The overall survival (OS) of EMD and non-EMD patients were 44 months and 82 months respectively (p < 0.001),and the progression-free survival were 24 months and 36 months respectively (p = 0.014). Multivariate analysis showed EMD at diagnosis, hypercalcemia, and elevated LDH were independent prognostic factors. Prevalence of anemia, elevated LDH, 1q21 + were greater in EMD-S and OS of EMD-S was significantly poorer (51months vs 26 months, p = 0.0067) compared with EMD-B. Autologous hematopoietic stem cell transplantation (auto-HSCT) could partly overcome the adverse effect of EMD. Highlights: EMD and EMD-S at diagnosis predict poor prognosis in MM. EMD and EMD-S had high incidence of IGH/FGFR3 rearrangement and 1q21 + respectively. Auto-HSCT prolongs both EMD and EMD-S patients' PFS.
- Is Part Of:
- Leukemia research. Volume 115(2022)
- Journal:
- Leukemia research
- Issue:
- Volume 115(2022)
- Issue Display:
- Volume 115, Issue 2022 (2022)
- Year:
- 2022
- Volume:
- 115
- Issue:
- 2022
- Issue Sort Value:
- 2022-0115-2022-0000
- Page Start:
- Page End:
- Publication Date:
- 2022-04
- Subjects:
- Multiple myeloma -- Extramedullary disease -- Cytogenetic risk -- Poor prognosis -- Retrospective study
Leukemia -- Periodicals
Leukemia -- Periodicals
Leucémie -- Périodiques
Leukemia
Periodicals
Electronic journals
Electronic journals
616.9941905 - Journal URLs:
- http://www.sciencedirect.com/science/journal/01452126 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.leukres.2022.106793 ↗
- Languages:
- English
- ISSNs:
- 0145-2126
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5185.270000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 21283.xml